Adoptive cell therapy for acute myeloid leukemia

References

• Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?. Ther Adv Hematol. 2018;9:135–148.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120–2130.
   PubMed Web of Science ®Google Scholar
• Xiao H, Li L, Pang Y, et al. Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia. Ann Hematol. 2018;97:2479–2490.
   Web of Science ®Google Scholar
• Liu L, Chang YJ, Xu LP, et al. Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after Allo-HSCT. Biol Blood Marrow Transplant. 2018;24:1350–1359.
   PubMed Web of Science ®Google Scholar
• Bachireddy P, Hainz U, Rooney M, et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014;123:1412–1421.
   PubMed Web of Science ®Google Scholar
• Hofmann S, Schmitt M, Gotz M, et al. Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. Int J Cancer. 2018. doi:10.1002/ijc.31753.
   Web of Science ®Google Scholar
• Introna M, Lussana F, Algarotti A, et al. Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:2070–2078.
   PubMedGoogle Scholar
• Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20:1785–1790.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Fukuda T, Nakashima M, et al. Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the japan marrow donor program. Biol Blood Marrow Transplant. 2017;23:938–944.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4:1245–1253.
   PubMed Web of Science ®Google Scholar
• Xuan L, Fan ZP, Zhang Y, et al. Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi. 2018;57:351–354.
   PubMedGoogle Scholar
• Campregher PV, Mattos VRP, Salvino MA, et al. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases. Einstein (Sao Paulo). 2017;15:355–358.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rautenberg C, Kruger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2018;97:335–342.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant. 2015;21:653–660.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27:1229–1235.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010;45:627–632.
   PubMed Web of Science ®Google Scholar
• Steinmann J, Bertz H, Wasch R, et al. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant. 2015;50:690–695.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138–150.
   PubMed Web of Science ®Google Scholar
• Mo XD, Zhang XH, Xu LP, et al. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017;96:829–838.
   PubMed Web of Science ®Google Scholar
• He F, Warlick E, Miller JS, et al. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant. 2016;51:1107–1112.
   PubMed Web of Science ®Google Scholar
• Bar M, Flowers MED, Storer BE, et al. Reversal of low donor chimerism after hematopoietic cell transplantation using pentostatin and donor lymphocyte infusion: a prospective phase II multicenter trial. Biol Blood Marrow Transplant. 2018;24:308–313.
   PubMedGoogle Scholar
• Gilman AL, Leung W, Cowan MJ, et al. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation. Am J Hematol. 2018;93:169–178.
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu QF, Wu DP, et al. Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant. 2017;23:1311–1319.
   PubMed Web of Science ®Google Scholar
• Legrand F, Le Floch AC, Granata A, et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplant. 2017;52:620–621.
   PubMed Web of Science ®Google Scholar
• Chang X, Zang X, Xia CQ. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2016;51:324–332.
   PubMed Web of Science ®Google Scholar
• Toprak SK. Donor lymphocyte infusion in myeloid disorders. Transfus Apher Sci. 2018;57:178–186.
   PubMed Web of Science ®Google Scholar
• Saillard C, Bisbal M, Sannini A, et al. Fatal acute respiratory distress syndrome with diffuse alveolar damage: donor lymphocyte infusion imputability?. Eur Respir J. 2016;48:1794–1796.
   PubMed Web of Science ®Google Scholar
• Castagna L, Sarina B, Bramanti S, et al. Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfus Apher Sci. 2016;54:345–355.
   PubMed Web of Science ®Google Scholar
• Wei YQ, Cen XN, Liu HH, et al. Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies. Oncol Lett. 2017;13:4101–4108.
   PubMed Web of Science ®Google Scholar
• Kordelas L, Buttkereit U, Lindemann M, et al. alphabeta-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:1668–1670.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8:625–632.
   PubMed Web of Science ®Google Scholar
• Ghobadi A, Choi J, Fiala MA, et al. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leuk Res. 2016;49:1–6.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;179:598–605.
   PubMed Web of Science ®Google Scholar
• Mo X, Zhang X, Xu L, et al. Interferon-alpha salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Front Med. 2018. doi:10.1007/s11684-017-0599-3
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465.
   PubMed Web of Science ®Google Scholar
• Bachireddy P, Wu CJ. Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology. 2014;3:e28187.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Chimeric antigen receptor t cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018;200:459–468.
   PubMed Web of Science ®Google Scholar
• Blum S, Martins F, Lubbert M. Immunotherapy in adult acute leukemia. Leuk Res. 2017;60:63–73.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145–1154.
   PubMed Web of Science ®Google Scholar
• Perna F, Berman SH, Soni RK, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32:506–519. e505.
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
   PubMed Web of Science ®Google Scholar
• Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106:4086–4092.
   PubMed Web of Science ®Google Scholar
• Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637–1647.
   PubMed Web of Science ®Google Scholar
• Kim MY, Yu KR, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439–1453. e1419.
   PubMed Web of Science ®Google Scholar
• Fan M, Li M, Gao L, et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. J Hematol Oncol. 2017;10:151.
   Web of Science ®Google Scholar
• Lichtenegger FS, Krupka C, Haubner S, et al. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol. 2017;10:142.
   PubMed Web of Science ®Google Scholar
• Wang QS, Wang Y, Lv HY, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184–191.
   PubMed Web of Science ®Google Scholar
• Lihua Budde JYS, Young K, Suzette B, et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood. 2017;130:811.
   Web of Science ®Google Scholar
• Katherine DCNF, Nelson AM, Aliza S, et al. Treating relapsed/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood. 2017;130:1359.
   Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21:2122–2129.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Sauer T, Shum T, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 2017;25:2202–2213.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 2015;22:484–488.
   PubMed Web of Science ®Google Scholar
• Kugler M, Stein C, Kellner C, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol. 2010;150:574–586.
   PubMed Web of Science ®Google Scholar
• Petrov JC, Wada M, Pinz KG, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 2018;32:1317–1326.
   PubMed Web of Science ®Google Scholar
• Liu F. First-in-human CLL1-CD33 compound CAR T cells as a two -pronged approach for the treatment of refractory acute myeloid leukemia. Paper presented at: Indication for specific and gene-modified cell therapy. 23rd Congress of the European Hematology Association 2018; 2018 June 14–17; Stockholm, Sweden.
   Google Scholar
• O'Hear C, Heiber JF, Schubert I, et al. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica. 2015;100:336–344.
   PubMed Web of Science ®Google Scholar
• Klingemann H. Are natural killer cells superior CAR drivers?. Oncoimmunology. 2014;3:e28147.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433–440.
   PubMed Web of Science ®Google Scholar
• Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23:492–500.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411–2419.
   PubMed Web of Science ®Google Scholar
• Koehl U, Sorensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261–266.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835–1838.
   PubMed Web of Science ®Google Scholar
• Stern M, Passweg JR, Meyer-Monard S, et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant. 2013;48:433–438.
   PubMed Web of Science ®Google Scholar
• Muller S, Schulz A, Reiss U, et al. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant. 1999;24:575–581.
   PubMed Web of Science ®Google Scholar
• Jaiswal SR, Zaman S, Nedunchezhian M, et al. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. Cytotherapy. 2017;19:531–542.
   PubMed Web of Science ®Google Scholar
• Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638–644.
   PubMed Web of Science ®Google Scholar
• Schneidawind D, Pierini A, Negrin RS. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood. 2013;122:3116–3121.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Campos C, Pera A, et al. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?. Cancer Immunol Immunother. 2016;65:453–463.
   PubMed Web of Science ®Google Scholar
• Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014;20:696–704.
   PubMed Web of Science ®Google Scholar
• Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99:3661–3667.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Jco. 2010;28:955–959.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Kang G, et al. Natural killer cell therapy in children with relapsed leukemia. Pediatr Blood Cancer. 2015;62:1468–1472.
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, Parisi S, et al. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res. 2016;22:1914–1921.
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Le Luduec JB, Forlenza C, et al. Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:705–709.
   PubMed Web of Science ®Google Scholar
• Sinha C, Cunningham LC. An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia. Pediatr Blood Cancer. 2016;63:2078–2085.
   PubMed Web of Science ®Google Scholar
• Oelsner S, Friede ME, Zhang C, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19:235–249.
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20:1287–1294.
   PubMed Web of Science ®Google Scholar
• Tang X, Yang L, Li Z, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083–1089.
   PubMed Web of Science ®Google Scholar
• Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74–95.
   PubMed Web of Science ®Google Scholar
• Anguille S, Willemen Y, Lion E, et al. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy. 2012;14:647–656.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999;104:173–180.
   PubMed Web of Science ®Google Scholar
• Serrano-Lopez J, Sanchez-Garcia J, Serrano J, et al. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. Transfusion. 2011;51:1546–1555.
   PubMed Web of Science ®Google Scholar
• Tan YF, Sim GC, Habsah A, et al. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia. Malays J Pathol. 2008;30:73–79.
   PubMedGoogle Scholar
• Senju S, Hirata S, Motomura Y, et al. Pluripotent stem cells as source of dendritic cells for immune therapy. Int J Hematol. 2010;91:392–400.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Collins RH, Jr., Blum W, et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer. 2017;123:3061–3072.
   PubMed Web of Science ®Google Scholar
• Van Driessche A, Van de Velde AL, Nijs G, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009;11:653–668.
   PubMed Web of Science ®Google Scholar
• Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130:1713–1721.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, van Wetering S, Santegoets S, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;10:1505–1518.
   PubMed Web of Science ®Google Scholar
• Cummins KD, Gill S. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Leuk Lymphoma 2018:1539–1553.
   Google Scholar
• Lee DA, Denman CJ, Rondon G, et al. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 2016;22:1290–1298.
   Google Scholar